Safety and Efficacy of Miglustat in Chinese NPC Patients

NCT ID: NCT03910621

Last Updated: 2025-03-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE4
• Total Enrollment: 17 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-04-02
• Study Completion Date: 2022-03-25

Brief Summary

This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study.

Approximately 19 subjects with Niemann Pick Type C disease (NPC) will be enrolled in this study. The study will be conducted at 2 sites in China.

Detailed Description

This is a prospective, multi-center, open-label, non-randomized, single-arm Phase IV confirmatory study.The study is conducted in Chinese subjects aged 4 years and older with Niemann Pick Type C disease (NPC). Approximately 19 subjects will be enrolled in this study. The study will be conducted at 2 sites in China. Patients will be treated with miglustat for 12 months, efficacy and safety outcomes will be measured

Conditions

Niemann-Pick Disease, Type C

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Miglustat

Miglustat is administered three times a day as an oral capsule

Group Type: EXPERIMENTAL

Miglustat

Intervention Type: DRUG

capsule, oral use

Interventions

Miglustat

capsule, oral use

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Patients with confirmed 2 pathogenic mutations in either Niemann Pick Type C Gene 1 or 2 (NPC 1 or NPC 2) or 1 pathogenic mutation in either NPC1 or NPC2 plus a positive biomarker (oxysterol or lysosphingolipids or bile acids) plus high clinical suspicion
• Signed informed consent prior to any study-mandated procedure.
• For subjects who are younger than 18 years consent must be sought of at least one legal guardian who shall sign the informed consent form and indicate the relationship between him/her and the subject.
• Subjects who are 18 years or older must sign the consent. If the subject cannot make an independent decision to participate in the study, consent must be sought of the legal agents who shall sign the informed consent form and indicate the relationship between him/her and the subject.
• Male and female subjects aged 4 years and older.
• Subjects who can performed the tests for the horizontal and vertical saccadic eye movements;
• Subjects who are able to swallow the study drug;
• Women of childbearing potential are only eligible if the following applies:
• Negative urine pregnancy test at screening.
• Agreement to undertake monthly urine pregnancy tests during the study and up to at least 30 days after study treatment discontinuation.
• Agreement to use one of the methods of birth control / follow the contraception scheme from screening up to at least 30 days after study treatment discontinuation.
• A fertile male (physiologically capable of fathering a child according to investigator's judgment) is eligible only if he agrees to use a condom during the treatment period and for an additional 12 weeks after treatment discontinuation.

Exclusion Criteria

• Subjects suffering from clinically significant diarrhea (>3 liquid stools per day for >7 days) without definable cause within 3 months before enrollment.
• Known hypersensitivity to the investigational treatment or drugs of the same class, or any of their excipients.
• Subjects who suffer from renal insufficiency with a creatinine clearance rate (CCR) of < 30ml/min per 1.73m2.
• Pregnant, planning to be become pregnant or lactating females, not using reliable birth control male adult subjects.
• Previous exposure to investigational treatment for more than 12 months before study start.
• Planned or current treatment with another investigational treatment up to 3 months prior to randomization. Symptomatic therapies are allowed (such as curcumin).
• Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results, such as drug or alcohol dependence or psychiatric disease, end stage disease including wheelchair bound patients, bedridden patients etc.
• Subjects who are judged unqualified for the clinical trial by the investigator.
• Subjects who suffer lysosomal storage diseases, enzyme deficiency or neurological diseases other than NPC.
• Subjects who suffer variant filipin staining without confirmatory genetic diagnosis of NPC.
• Subjects with uncontrolled epilepsy.
• Subjects with complete ophthalmoplegia.
• Known concomitant life-threatening disease with a life expectancy < 12 months.

• Minimum Eligible Age: 4 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Actelion

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Yue Wu

Role: STUDY_DIRECTOR

Janssen China R&D

Locations

Peking University first Hospital

Beijing, , China

Xin Hua Hospital, Shanghai Jiao Tong University

Shanghai, , China

Countries

China

References

Zhang H, Xiong H, Wei C, Yi M, Che Y, Zhuo J, Li X. Evaluation of the safety and efficacy of miglustat for the treatment of Chinese patients with Niemann-Pick disease type C: A prospective, open-label, single-arm, phase IV trial. Intractable Rare Dis Res. 2024 Nov 30;13(4):227-235. doi: 10.5582/irdr.2024.01056.

Reference Type: DERIVED

PMID: 39628618 (View on PubMed)

Other Identifiers

AC-056C405

Identifier Type: -

Identifier Source: org_study_id